June 9, 2021

FDA Approval of a New Treatment: What’s Next for the Alzheimer’s Community?

Thumbnail

FDA Approval of a New Treatment: What’s Next for the Alzheimer’s Community?

About This Episode

The Food and Drug Administration (FDA) has approved aducanumab as a new treatment for early-stage Alzheimer’s disease, and this AlzTalks explores what this means for the Alzheimer’s community.

Host Meryl Comer talked about the drug treatment with Biogen’s Samantha Budd Haeberlein, PhD, SVP, Head of Neurodegeneration Development and Karin Hellsvik, Head, External Communications and Patient Advocacy, and had a conversation about the decision with George Vradenburg, chairman and co-founder of UsAgainstAlzheimer’s; Russ Paulsen, UsA’s chief operating officer; and Jason Resendez, executive director of the UsAgainstAlzheimer’s Center for Brain Health Equity. 

Meryl Comer also spoke about this new drug with advocates Jim and Geri Taylor. Geri, who lives with Alzheimer’s disease, participated in the clinical trial for this therapy.

Press the 'Play' button under the image at left to hear a podcast of the conversation, or watch the full session HERE.

BrainStorm Feed

90

The Longevity Paradox: Health Span vs. Life Span with Paul Irving

What's the purpose of a long life if our brains can't enjoy it? Paul Irving, Senior Advisor at the Milken Institute on the Future of Longevity and Dean of Faculty at USC's Leonard Davis School of Gerontology, challenges conventional thinking about aging and longevity in a conversation with host, Meryl Comer.
LISTEN NOW
89

Paul Irving and The Invisible Workforce: Why Caregiving is a Personal and an Economic Crisis

In this episode of BrainStorm, Paul Irving discusses the PBS documentary produced by Bradley Cooper called Caregiving with host Meryl Comer.
LISTEN NOW
88

Breaking the Silence: Jay Reinstein’s Mission to End Alzheimer's Stigma

In this episode of BrainStorm, host Meryl Comer talks with Jay Reinstein, a former assistant city manager in North Carolina, about his 12 to15-month journey involving neuropsychological testing and brain scans before being diagnosed with early-onset Alzheimer's at age 57.
LISTEN NOW